51 results about "Late onset" patented technology

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)α-HTBZ) is used in the methods described herein for treating a subject in need thereof.

The present invention relates generally to methods for treating early and late onset pre-eclampsia, as well as to methods of screening for and predicting the likelihood that a pregnant female patient will develop early and / or late pre-eclampsia, by assessing specific combinations of factors. In the methods of the invention, the a priori risk of developing eariy preeclampsia may be calculated utilizing coefficients for each of the maternal factors (binary variables), the coefficients being generated utilizing logistic regression analysis. The a posteriori risk of developing eariy pre-eclampsia may be calculated utilizing coefficients for each of the patient-specific factors, the coefficients being generated utilizing logistic regression analysis.

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.

The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.

The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.

Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.

A medical application of S-adenosine homocysteine in preparing immunodepressant with high effect and low poison is disclosed.

The invention discloses test paper for quickly screening late onset severepre-eclampsia. The test paper for quickly screening late onset severepre-eclampsia comprises optional test paper for detectingthe APELA concentration in blood or urine. The invention also discloses a kit for screening late onset severepre-eclampsia. The kit comprises an optional reagent for detecting the APELA concentrationin blood or urine. The invention also discloses application of the test paper for detecting the APELA concentration in blood or urine in preparing the test paper for screening late onset severepre-eclampsia. The invention also discloses application of the reagent for detecting the APELA concentration in blood or urine in preparing a reagent for screening late onset severepre-eclampsia. Accordingto the test paper and the kit for quickly screening late onset severepre-eclampsia disclosed by the invention, only blood and urine of a patient need to be acquired, and whether the patient is suffered from late onset severepre-eclampsia or not can be screened, so that the test paper and the kit can be used for noninvasively, effectively and quickly examining and screening late onset severepre-eclampsia, and are convenient to use and favorable in clinic application prospect.